Besides single‐agent activity, we provided evidence that targeting β2AR can potentiate the anti‐tumor effects of bortezomib and melphalan in multiple myeloma cells, identifying the potential of propranolol to enhance the effect of current standard‐of‐care agents in multiple myeloma. Here, ADRB2 is linked to neoplasm.